Cancer Expenditures and Mortality Trends in Brazil: An Ecological Population‐Level Time‐Series Analysis, 2008–2023 Authors: Larissa Saldanha Fonseca, Leonardo Paredes Pires, Luciana Magalhães Rebelo Alencar, Eduardo Ricci‐Junior, Ralph Santos‐Oliveira Published: 2026 ABSTRACT ABSTRACTBackgroundBrazil has substantially expanded public oncology investment over the past decade, particularly within the Brazilian Unified Health System (SUS). However, whether increased spending has translated into measurable population‐level improvements in cancer outcomes remains uncertain.MethodsWe conducted a retrospective ecological time‐series analysis using national data from 2008 to 2023. Public expenditures for female breast and prostate cancer were extracted from DATASUS and inflation‐adjusted, while mortality data were obtained from INCA and age‐standardized. Key policy milestones—RDC 55/2010, creation of Conitec in 2011, Ordinance No. 874/2013, and Constitutional Amendment 95/2016—were mapped against expenditure and mortality trends. Findings therefore represent system‐level associations rather than causal estimates of patient‐level therapeutic effectiveness.ResultsOncology expenditures increased substantially, with more pronounced growth after 2011, whereas national age‐standardized mortality rates for female breast and prostate cancer changed comparatively little. This pattern represents a descriptive temporal divergence between expenditure growth and mortality trends, not evidence of therapeutic inefficacy or a quantified causal effect. Regional differences in diagnostic capacity, healthcare infrastructure, continuity of care, and treatment timeliness may influence how financial inputs translate into population‐level outcomes.ConclusionsBrazil's experience supports a value‐oriented oncology strategy linking investment not only to technology incorporation, but also to early diagnosis, implementation capacity, regional equity, and effective care pathways. These ecological findings do not support individual‐level causal inference, particularly for prostate cancer, for which mortality is a delayed and relatively insensitive medium‐term endpoint. Future studies should incorporate stage at diagnosis, treatment pathways, time‐to‐treatment indicators, and regional survival data. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, placing substantial clinical, emotional, and economic burdens on societies and healthcare systems. In Brazil, the epidemiological transition characterized by aging populations and changes in lifestyle has amplified the impact of non‐communicable diseases, particularly cancer. According to the Global Cancer Observatory (GLOBOCAN), Brazil recorded an estimated 625,000 new cancer cases in 2022 alone, with breast, prostate, lung, and colorectal cancers representing the most frequent diagnoses. The financial implications of this trend have become increasingly significant, especially in the context of universal healthcare provided by the Sistema Único de Saúde (SUS), which is tasked with delivering comprehensive cancer prevention, diagnosis, treatment, and palliative care services to over 210 million citizens [1, 2, 3]. Over the past 15 years, the Brazilian government has intensified investment in oncology, aiming to expand access, incorporate new technologies, and strengthen specialized care. These efforts include the National Policy for Cancer Prevention and Control, financing of high‐complexity oncology centers (UNACONs and CACONs), and incorporation of high‐cost anticancer technologies into SUS pathways [4, 5]. A central policy question is whether growth in financial inputs is accompanied by commensurate improvement in population‐level outcomes and access. In the present study, this question is examined descriptively at the national aggregate level rather than through patient‐level effectiveness or formal cost‐effectiveness analysis. Health economics literature has long emphasized the importance of value‐based healthcare, in which expenditures are assessed against gains in survival, quality of life, access, and other clinically meaningful outcomes. In oncology, this question is especially salient because treatment pathways increasingly incorporate high‐cost medicines, biologics, precision diagnostics, radiotherapy technologies, and supportive‐care interventions. Brazil provides a particularly informative setting for population‐level assessment because SUS combines universal coverage with pronounced geographic and socioeconomic heterogeneity. Despite these complexities, relatively few national ecological time‐series studies have examined whether temporal growth in SUS‐recorded cancer expenditure is accompanied by parallel changes in standardized mortality indicators. Previous studies have focused either on the cost‐effectiveness of specific drugs or on disease‐specific outcome metrics. However, a macroeconomic perspective that spans multiple cancer types, therapeutic modalities, and regional health networks over a decade or more is lacking. Such a comprehensive approach is vital for capturing the evolving dynamics of cancer treatment, including the introduction of precision oncology, immunotherapy, and new protocols for early detection and multimodal care [6, 7]. This study addresses this gap by analyzing national aggregate data from Brazil from 2008 to 2023 and integrating SUS‐recorded expenditure indicators with age‐standardized mortality trends for female breast and prostate cancer. Using publicly available information from DATASUS, INCA, IBGE, and official policy sources, we constructed an ecological population‐level time‐series framework to describe expenditure and mortality trajectories and to contextualize them against major health‐policy milestones. The unit of inference is the health system at the national annual level; no individual‐level linkage exists among expenditure, treatment exposure, clinical characteristics, or mortality. We therefore hypothesized that expenditure growth and population‐level mortality trajectories would not necessarily move proportionately over time and that any divergence would need to be interpreted in the context of demographic change, access, implementation capacity, and regional heterogeneity rather than as a direct measure of treatment effectiveness. In addition to describing these temporal patterns, the study seeks to inform national cancer‐control strategy by identifying system‐level tensions among expenditure growth, implementation capacity, access, and outcomes. The analysis is intended to support policy discussion on resource allocation, reimbursement, technology incorporation, and care delivery while explicitly avoiding patient‐level causal inference or claims of direct therapeutic effectiveness. Ultimately, this work contributes to the global discourse on sustainable cancer care and the principles of equity, efficiency, and efficacy in health system design. Brazil's experience, as a middle‐income country with universal health coverage and increasing cancer prevalence, provides valuable lessons for other nations facing similar demographic and economic pressures. The findings are expected to inform not only national health planning but also regional and global initiatives in cancer economics and public health policy. Methodology Study Design and Scope This study is an ecological, population‐level time‐series analysis conducted to evaluate temporal co‐movement between SUS‐recorded public expenditures for female breast and prostate cancer care and national age‐standardized mortality indicators in Brazil from 2008 to 2023. The unit of analysis was the national calendar‐year aggregate. Annual SUS expenditure was treated as a population‐level exposure indicator and annual age‐standardized mortality as a population‐level outcome indicator. The design does not include individual‐level exposure ascertainment, patient follow‐up, or linkage between reimbursement and mortality records. Accordingly, all findings are interpreted at the health‐system level and are not used to infer whether individual patients receiving higher‐cost care experienced better or worse clinical outcomes. The ecological nature of the data, the risk of cross‐level inference, and the limitations of administrative and mortality databases are addressed in a consolidated Subsection 3.6. Data Sources We utilized publicly accessible, national‐level datasets from: DATASUS (Departamento de Informática do SUS): For financial expenditures, hospitalizations (AIH), and outpatient procedures (APAC) related to oncology. INCA (Instituto Nacional de Câncer): For cancer incidence and mortality statistics. IBGE (Instituto Brasileiro de Geografia e Estatística): For demographic and socioeconomic data. Official legal and regulatory publications: Including the implementation timelines of RDC 55/2010, Conitec [8], Ordinance No. 874/2013, and Constitutional Amendment 95/2016. DATASUS (Departamento de Informática do SUS): For financial expenditures, hospitalizations (AIH), and outpatient procedures (APAC) related to oncology. DATASUS (Departamento de Informática do SUS): For financial expenditures, hospitalizations (AIH), and outpatient procedures (APAC) related to oncology. INCA (Instituto Nacional de Câncer): For cancer incidence and mortality statistics. INCA (Instituto Nacional de Câncer): For cancer incidence and mortality statistics. IBGE (Instituto Brasileiro de Geografia e Estatística): For demographic and socioeconomic data. IBGE (Instituto Brasileiro de Geografia e Estatística): For demographic and socioeconomic data. Official legal and regulatory publications: Including the implementation timelines of RDC 55/2010, Conitec [8], Ordinance No. 874/2013, and Constitutional Amendment 95/2016. Official legal and regulatory publications: Including the implementation timelines of RDC 55/2010, Conitec [8], Ordinance No. 874/2013, and Constitutional Amendment 95/2016. For the purposes of this study, expenditure estimates represent SUS‐recorded oncology‐related administrative spending identifiable in national reimbursement databases, including hospitalizations (AIH) and outpatient high‐complexity procedures (APAC). These values should not be interpreted as the full societal or full‐pathway costs of breast and prostate cancer care. In particular, decentralized screening campaigns, broad primary‐care diagnostic activities, and some upstream referral‐related expenditures may be incompletely captured or absent from the analyzed financial series. Inclusion Criteria Cancer types: Female breast cancer (ICD‐10 C50) and prostate cancer (ICD‐10 C61). Temporal scope: Data spanning 2008–2023 to align with major health policy shifts. Financial indicators: Annual public expenditures categorized by procedures, hospitalizations, pharmaceuticals (including biosimilars), and infrastructure. Population‐level outcomes: National age‐standardized mortality rates for female breast cancer and prostate cancer, derived from the INCA Atlas On‐line de Mortalidade and standardized to the world standard population. Cancer types: Female breast cancer (ICD‐10 C50) and prostate cancer (ICD‐10 C61). Cancer types: Female breast cancer (ICD‐10 C50) and prostate cancer (ICD‐10 C61). Temporal scope: Data spanning 2008–2023 to align with major health policy shifts. Temporal scope: Data spanning 2008–2023 to align with major health policy shifts. Financial indicators: Annual public expenditures categorized by procedures, hospitalizations, pharmaceuticals (including biosimilars), and infrastructure. Financial indicators: Annual public expenditures categorized by procedures, hospitalizations, pharmaceuticals (including biosimilars), and infrastructure. Population‐level outcomes: National age‐standardized mortality rates for female breast cancer and prostate cancer, derived from the INCA Atlas On‐line de Mortalidade and standardized to the world standard population. Population‐level outcomes: National age‐standardized mortality rates for female breast cancer and prostate cancer, derived from the INCA Atlas On‐line de Mortalidade and standardized to the world standard population. Data Processing and Analysis Expenditure Aggregation All nominal expenditure values originally extracted in Brazilian reais (BRL) were first adjusted to 2023 BRL using the Brazilian Extended National Consumer Price Index (IPCA), the official consumer‐price inflation index produced by IBGE. Inflation‐adjusted values were then converted to U.S. dollars using the Banco Central do Brasil PTAX BRL/USD exchange rate for 29 December 2023, the final business day of 2023 (BRL 4.8413 per USD). The single‐date conversion was used only to facilitate international readability and comparison; it was not intended to reconstruct year‐specific foreign‐exchange exposure. Accordingly, all USD values should be interpreted as constant‐2023‐BRL purchasing‐power estimates expressed in a common international currency, rather than as contemporaneous nominal USD expenditures for each year. Constant BRL remains the underlying inflation‐adjusted economic series. Importantly, the expenditure series reflect recorded SUS administrative spending and do not permit complete classification by therapeutic intent. Thus, the available data do not robustly distinguish curative‐intent interventions from palliative or chronic disease management in all cases, particularly for prostate cancer, where long‐term androgen deprivation therapy may be used across multiple clinical settings. Likewise, the database architecture does not allow full allocation of expenditures across primary, secondary, and tertiary levels of care with sufficient consistency for national longitudinal analysis. Mortality Indicators and Population‐Level Outcome Assessment Mortality data were interpreted using age‐standardized mortality rates calculated by the direct method against the world standard population, as reported through INCA's national mortality platform. Age‐standardized rates were designated a priori as the primary mortality metric because they reduce confounding by changes in population size and age structure. Absolute death counts were retained only as descriptive indicators of burden and were not treated as evidence of temporal change in mortality risk. The expenditure–mortality comparison was therefore framed as a descriptive assessment of whether the direction and magnitude of change in inflation‐adjusted SUS expenditure appeared proportionate to the direction of standardized mortality trends. No patient‐level treatment‐effect estimate was attempted, and no claim of causality was made. Mortality was selected as a population‐level endpoint of public health relevance; however, it has important interpretive limitations, especially for prostate cancer. Given the frequently indolent natural history of prostate malignancy, mortality may be insufficiently sensitive to detect the medium‐term effects of changes in screening, diagnosis, and treatment delivery over a 15‐year analytic horizon. More responsive indicators—such as stage at diagnosis, interval from suspicion to biopsy, and time from diagnosis to treatment initiation—would strengthen assessment of system effectiveness, but these variables were not available in sufficiently standardized and nationally harmonized form across the full study period. Descriptive Policy‐Milestone Assessment Key policy events, including RDC 55/2010, Conitec implementation in 2011, Ordinance No. 874/2013, and Constitutional Amendment 95/2016, were descriptively mapped onto national aggregate expenditure and mortality trends. This assessment was intended to contextualize temporal patterns rather than to estimate formal causal policy effects. Interrupted time‐series designs require adequately separated pre‐ and post‐intervention observations, an a priori impact model, careful treatment of autocorrelation and time‐varying confounding, and a clearly defined intervention point [9]. In the present series, four major policy milestones occurred within a relatively short 9‐year window, creating overlapping exposure periods and insufficient independent annual segments for stable policy‐specific level and slope estimation. Formal segmented interrupted time‐series coefficients were therefore not reported, and no counterfactual or policy‐specific causal effect was inferred. Statistical Tools Data were processed using R (version 4.2.3) and Stata (version 17). The analytical strategy was deliberately descriptive because the available annual national series contains a small number of temporally ordered aggregate observations and because the manuscript does not include a patient‐level or region‐year analytic dataset that would support robust multivariable inference. Temporal trajectories were summarized graphically and interpreted using the age‐standardized mortality series as the primary outcome framework. We did not report generalized least‐squares coefficients, Pearson/Spearman correlation coefficients, or regional Gini/Theil indices because such estimates were not supported by a fully reported analytic dataset with the diagnostics, uncertainty estimates, and reproducible region‐year inputs required for defensible inference. Consequently, terms such as “weak correlation” were removed and replaced by “descriptive temporal divergence” or “limited proportional co‐movement.” Regional inequality is discussed as contextual evidence from published Brazilian health‐system literature rather than as a numerical inequality result generated by this study. Ethical Considerations This study utilized anonymized, secondary public data and did not involve human subjects or intervention. Thus, it was exempt from institutional ethical review in accordance with Brazilian Resolution CNS 510/2016. Breast and Prostate Cancer in Brazil: Mortality, Expenditures, and Policy Contexts Breast Cancer Mortality and Public Health Challenges Breast cancer continues to represent a substantial public health concern in Brazil, with mortality rising steadily over recent decades. This increase is driven by a complex interplay of demographic, behavioral, and systemic factors. The growing incidence is associated with urbanization and lifestyle shifts, including sedentary behavior, unhealthy diets, increased alcohol consumption, and delayed childbearing. Figure 1 illustrates the absolute number of female breast cancer deaths in Brazil between 1979 and 2021 and should be interpreted as a descriptive indicator of mortality burden rather than an age‐standardized mortality rate trend [12, 13]. Female breast cancer mortality burden in Brazil, 1979–2021. Annual absolute number of female breast cancer deaths in Brazil. The y‐axis represents mortality counts. These counts are descriptive burden indicators and are influenced by incidence, population growth, and population aging; they should not be interpreted as age‐standardized mortality rates. Although public policies have targeted breast cancer control—such as mammography programs, educational campaigns, and the establishment of specialized care units—these efforts have yet to yield significant mortality reductions [10]. Structural barriers, including delayed diagnosis, regional disparities in access to screening and oncologic care, and insufficient integration between primary and specialized services, continue to impede progress [11]. Mortality reduction in breast cancer requires more than isolated interventions; it necessitates systemic investment in rapid diagnostic pathways, equitable distribution of resources, and sustained implementation of evidence‐based therapeutic protocols across Brazil's heterogeneous healthcare landscape. Over the past four decades, the absolute burden of breast cancer mortality has increased, but this count‐based pattern cannot by itself establish deterioration in age‐standardized mortality risk or failure of cancer‐control interventions [14]. Persistent late‐stage presentation and uneven diagnostic and referral capacity remain important concerns, particularly in lower‐resource settings, and support continued emphasis on early detection, timely diagnostic confirmation, and coordinated treatment pathways. Prostate Cancer: A Parallel Challenge Similar to breast cancer, prostate cancer is characterized by increasing incidence and a growing burden on Brazil's health system. Screening strategies, particularly prostate‐specific antigen (PSA) testing, have the potential to enable early diagnosis, improve therapeutic outcomes, and reduce overall healthcare expenditure [15, 16]. However, these benefits are contingent upon equitable access to screening and timely treatment. Prostate cancer predominantly affects men over the age of 50, and its etiology is closely linked to hereditary factors and racial disparities [17]. Men with a family history face up to tenfold increased risk, and incidence is notably higher in Afro‐Brazilian populations [18]. As Brazil's population ages and socioeconomic transitions continue, the demand for effective prostate cancer management is accelerating. Despite growing awareness, the absolute number of prostate cancer deaths in Brazil has increased, albeit at a slower pace (Figure 2); this count‐based trend should be interpreted as mortality burden rather than an age‐standardized mortality rate trend. This trend underscores the need for improved health system responsiveness, particularly in underserved areas. Delayed diagnoses and inconsistent follow‐up are common, diminishing the potential gains from early detection. The health system's primary challenge lies in ensuring that early diagnostic efforts are not only initiated but also translated into effective and timely treatment pathways. Prostate cancer mortality burden in Brazil, 1979–2021. Annual absolute number of prostate cancer deaths in Brazil. The y‐axis represents mortality counts. These counts are descriptive burden indicators and are influenced by incidence, population growth, and population aging; they should not be interpreted as age‐standardized mortality rates. Oncologic Expenditures: Economic Pressures and Policy Evolution The financial burden of cancer treatment in Brazil increased over the observed period. Between 2008 and 2021, SUS‐recorded expenditures related to breast and prostate cancer rose substantially, as illustrated in Figure 3. This growth is temporally consistent with increasing disease burden, expansion of services, and incorporation of higher‐cost therapies and diagnostic technologies. The descriptive comparison with mortality should not be interpreted as demonstrating that expenditure itself caused, failed to cause, or was statistically associated with a specific change in standardized mortality. Breast and prostate cancer‐related SUS expenditures in Brazil, 2008–2021. Annual SUS‐recorded expenditures for breast and prostate cancer, expressed in 2023 USD. Public policies have attempted to regulate and optimize these expenditures through legal and institutional frameworks. Key legislative milestones include: RDC 55/2010, regulating biosimilar introduction in Brazil. The creation of Conitec in 2011 to evaluate and approve new technologies for incorporation into the SUS. Ordinance No. 874/2013, which formalized the network of CACONs and UNACONs. Constitutional Amendment 95/2016, which introduced a federal spending cap affecting all sectors, including health. RDC 55/2010, regulating biosimilar introduction in Brazil. RDC 55/2010, regulating biosimilar introduction in Brazil. The creation of Conitec in 2011 to evaluate and approve new technologies for incorporation into the SUS. The creation of Conitec in 2011 to evaluate and approve new technologies for incorporation into the SUS. Ordinance No. 874/2013, which formalized the network of CACONs and UNACONs. Ordinance No. 874/2013, which formalized the network of CACONs and UNACONs. Constitutional Amendment 95/2016, which introduced a federal spending cap affecting all sectors, including health. Constitutional Amendment 95/2016, which introduced a federal spending cap affecting all sectors, including health. These policies are depicted in Figure 4, which descriptively overlays each legal development onto the trend in oncologic expenditures. Although these regulatory measures shaped the operational framework of Brazilian oncology services, the present analysis cannot isolate their individual effects on expenditure containment, treatment accessibility, or mortality trends. Cancer‐related SUS expenditures and major oncology policy milestones in Brazil, 2008–2021. Annual Biosimilars and the Economics of Innovation One key strategy to control rising costs has been the introduction of biosimilars. These are biologic products highly similar to already‐approved reference products, intended to reduce drug costs through increased market competition. Examples include trastuzumab biosimilars for breast cancer and supportive agents like filgrastim [19]. However, despite regulatory approval and theoretical cost‐saving potential, Brazil has not yet realized significant reductions in oncology drug expenditures post‐2010. The complex manufacturing and regulatory pathways of biosimilars, coupled with patent challenges and limited domestic production capacity, have slowed their market penetration. Furthermore, public purchasing mechanisms and price negotiations within SUS have not sufficiently incentivized widespread biosimilar adoption [20]. This gap between regulatory authorization and practical cost reduction illustrates the challenges of translating biotechnological innovation into fiscal sustainability in low‐ and middle‐income countries. The Productive Development Partnerships (PDPs) aimed to address this gap by fostering collaborations between public institutions and domestic or international pharmaceutical firms. These partnerships were designed to localize production, ensure supply security, and reduce dependence on imports [21]. Despite some progress, the scale and speed of these initiatives have lagged behind expectations. Technology Incorporation and the Cost of Progress Following Conitec's establishment in 2011, the number of technologies incorporated into SUS rose sharply. From 2012 to 2019, 380 technologies were added, of which 177 (46.6%) were medications. Of these, 36 were specific to cancer care, including drugs, clinical protocols, and procedures. While this reflects an institutional commitment to innovation and improved care, it also contributes to rising costs, especially when not accompanied by cost‐effectiveness analyses and implementation plans tailored to Brazil's diverse health infrastructure. As Table 1 indicates, neoplasms are among the top categories of technological incorporation, which has implications for budgeting and policy prioritization. Technology‐driven cost escalation, particularly for proprietary oncologic drugs, has outpaced the ability of the public health system to contain expenditures without compromising access or equity. TABLE 1Type of technology incorporated by Conitec by category between 2012 and 2019: networked oncology care: UNACONs and CACONs.Types of technologyMedicationsPCDTProceduresProductsSome infectious and parasitic diseases511691Endocrine, nutritional and metabolic diseases201642Others a 53310Neoplasms151083 a Rare diseases without ICD, multiple diseases, and other situations without ICD. Type of technology incorporated by Conitec by category between 2012 and 2019: networked oncology care: UNACONs and CACONs. Rare diseases without ICD, multiple diseases, and other situations without ICD. The 2013 establishment of the National Policy for Cancer Prevention and Control restructured oncology care delivery within SUS. Specialized treatment centers—UNACONs for high‐incidence cancers and CACONs for complex or rare cases—were funded through high‐complexity care blocks [22]. However, geographic disparities in availability and capacity continue to affect timely access, particularly in rural and northern regions. With the population aging and cancer incidence rising, demand for specialized oncology services is projected to increase sharply. The sustainability of this model, particularly under the financial constraints imposed by Constitutional Amendment 95, remains uncertain. Spending Caps and the Future of Oncology Investment Constitutional Amendment 95 introduced a federal spending ceiling that freezes public expenditure growth in real terms for 20 years [23]. Since its implementation in 2016, growth in oncology‐related spending has moderated. Figure 3 demonstrates this deceleration. While initially interpreted as a form of fiscal discipline, concerns have emerged regarding its impact on the health sector's ability to adapt to rising demands, especially in technologically intensive fields like oncology. This policy environment risks stagnation in service expansion, technology incorporation, and equitable access—all of which are essential to improve cancer outcomes. Oncology, being highly dynamic and innovation‐driven, is particularly vulnerable to underinvestment, with repercussions for early diagnosis, therapeutic innovation, and long‐term survival. Cancer Spending and Mortality: Descriptive Expenditure–Outcome Divergence A descriptive comparison of inflation‐adjusted SUS expenditure and age‐standardized mortality trajectories indicates that the two series did not change proportionately over the observed period. This pattern should be interpreted as a system‐level temporal divergence, not as evidence that additional expenditure was clinically ineffective. The relationship may reflect multiple intervening mechanisms, including incidence, diagnostic stage, treatment access, service capacity, care continuity, technology diffusion, and regional implementation differences. Figures based on absolute deaths are retained solely as burden indicators and are not used to infer mortality risk. Factors contributing to this discrepancy include delays in diagnosis, limited access to standard‐of‐care therapies in some regions, inefficient resource allocation, and systemic barriers to follow‐up care. Moreover, social and regional inequalities play a significant role, with underserved areas experiencing higher mortality despite overall national spending increases. Discussion Persistent Mortality Despite Rising Expenditures The present analysis identifies a descriptive system‐level divergence within Brazil's oncology landscape: SUS‐recorded expenditure for breast and prostate cancer care increased substantially, whereas the corresponding age‐standardized mortality trajectories showed comparatively limited proportional change over the analytic period. Figures 1 and 2 display absolute death counts and therefore represent burden rather than mortality risk; these count‐based figures are influenced by population growth, population aging, incidence, and case ascertainment. The interpretation of expenditure–outcome performance is therefore anchored to standardized mortality rather than to the visual rise in absolute deaths. This pattern raises a health‐system question about how effectively additional financial inputs are translated into earlier diagnosis, timely treatment, continuity of care, and equitable service delivery, but it does not quantify a causal effect of spending on mortality. This temporal disjunction between financial input and population‐level mortality indicators raises concerns regarding the efficiency, equity, and system‐level responsiveness of oncologic investments under Brazil's Unified Health System (SUS). While increased financial allocation has been directed toward high‐cost biologics, advanced diagnostics, and institutional care models, outcomes suggest that these resources may not be sufficiently addressing upstream determinants of cancer survival—namely, early diagnosis and equitable access to timely treatment. Because this is an ecological analysis of secondary administrative and mortality data, the observed temporal divergence cannot establish that particular technologies, medicines, or models of care were ineffective. Expenditure and mortality were measured independently at the national aggregate level, and the analysis cannot determine treatment exposure, therapeutic response, or survival for individual patients. The appropriate inference is therefore limited to a descriptive health‐system observation: substantial growth in recorded expenditure was not mirrored by a proportionate national improvement in the selected standardized mortality indicators within the same observational window. Economic Pressures and Policy‐Milestone Context The substantial increase in cancer‐related expenditure shown in Figure 3 occurred during a period of expanding technology incorporation and specialized oncology capacity. Figure 4 places selected regulatory and legislative milestones on this trajectory to provide policy context. Because these events overlapped with demographic change, evolving incidence, reimbursement dynamics, and other health‐system developments, the overlay is descriptive and does not attribute the expenditure pattern to any single policy or technology. Key milestones such as RDC 55/2010 (biosimilar regulation), the formation of Conitec (2011), the institutional development of UNACON/CACON networks under the national oncology policy framework, and the fiscal restraint associated with Constitutional Amendment 95/2016 represent important contextual junctures. Each affected a different component of technology regulation, access, organization, or financing; however, the present descriptive overlay cannot estimate the independent contribution of any one milestone to expenditure or mortality trends. This restraint is particularly important because multiple interventions occurred within closely spaced periods, a circumstance that complicates segmented time‐series attribution and increases vulnerability to co‐intervention and time‐varying confounding [9]. For example, biosimilar regulation created a potential mechanism for improving competition and procurement efficiency, but the expenditure trajectory alone cannot determine the degree to which biosimilar uptake altered total oncology costs. Likewise, Conitec's incorporation of oncologic technologies contributed to the modernization and expansion of therapeutic options, but this study does not estimate the incremental clinical benefit or budget impact of individual technologies. The observed post‐2012 expenditure growth is compatible with several simultaneous processes, including service expansion, increasing case load, demographic aging, technology incorporation, coding changes, and changes in reimbursement intensity. These factors cannot be disentangled with the present national aggregate series. Institutional Infrastructure and Regional Disparities The establishment of specialized cancer care networks—UNACONs for prevalent tumors and CACONs for complex cases—represented a major structural advance. However, Figure 3 and related mortality data indicate that centralized investment in tertiary care alone has not sufficed to equalize outcomes across Brazil's socioeconomically and geographically diverse population. Rural and peripheral regions continue to struggle with access delays, lower screening uptake, and fragmented care continuity, all of which undermine the potential mortality benefits of late‐stage interventions. Regional heterogeneity is essential for interpreting the national findings. Brazilian studies have documented marked geographic differences in oncology infrastructure, service distribution, screening access, specialist availability, radiotherapy capacity, pathology access, and continuity of care [4, 11, 12]. National aggregates necessarily compress these distinct implementation environments into a single annual series. Accordingly, any national‐level divergence between expenditure growth and standardized mortality should not be interpreted as uniform inefficiency across the country. Rather, published evidence supports the plausibility that different regions possess unequal capacity to transform financial investment into timely diagnosis and effective longitudinal care. This study did not calculate region‐specific Gini or Theil indices, and no numerical inequality coefficient is claimed. Furthermore, the 2016 federal spending cap (Constitutional Amendment 95) introduced long‐term constraints on health sector growth. As illustrated in Figure 3, oncology spending appeared to decelerate after the cap's implementation. However, this descriptive temporal pattern cannot be attributed causally to Constitutional Amendment 95 alone, because other concurrent factors, including secular incidence trends, demographic aging, reimbursement dynamics, technology incorporation, and service‐capacity constraints, may also have influenced expenditure trajectories. Comparable constraints have been reported in other middle‐income public health systems, where regulatory authorization does not automatically translate into timely reimbursed access. In Bulgaria, for example, Kostadinov et al. reported that only 15 of 50 oncologic orphan medicines authorized by the European Medicines Agency were accessible nationally, with a median delay of 760 days from marketing authorization to inclusion in the positive drug list; expenditures for rare‐cancer orphan medicines also represented a growing budgetary burden during 2020–2023 [24]. Although the institutional and financing arrangements differ from SUS, this comparison reinforces a central conceptual point of the present study: expenditure growth, technology availability, reimbursement timing, and equitable real‐world access are related but non‐equivalent dimensions of cancer‐system performance. Descriptive Expenditure–Burden Comparison Figure 5 illustrates the temporal co‐occurrence of female breast cancer absolute death counts and SUS‐recorded breast cancer‐related expenditures from 2008 to 2021. The expenditure series refers specifically to breast cancer‐related administrative spending captured in DATASUS rather than total oncology expenditure or the full societal cost of breast cancer. Because the mortality axis uses absolute counts, Figure 5 is retained only to illustrate changes in burden alongside expenditure and is not used to estimate correlation, mortality risk, or treatment effectiveness. Female breast cancer death counts and breast cancer‐related SUS expenditures in Brazil, 2008–2021. Annual absolute female breast cancer deaths and SUS‐recorded breast cancer‐related expenditures. The expenditure series refers specifically to breast cancer‐related administrative spending captured in DATASUS and does not represent total cancer expenditure. Death counts are descriptive burden indicators and should not be interpreted as age‐standardized mortality rates. This figure is not used as the primary basis for mortality‐trend inference. This descriptive divergence should not be interpreted as direct evidence that increased disease‐specific spending failed to reduce age‐standardized mortality risk. Absolute death counts are affected by incidence, case load, demographic aging, population growth, stage at diagnosis, diagnostic delay, regional access, treatment continuity, and other factors not linked to expenditure at the individual level. Therefore, the count‐based comparison in Figure 5 may visually exaggerate the apparent expenditure–mortality association because both expenditure and absolute deaths may increase over time partly as a function of growing disease burden rather than changes in the probability of dying from breast cancer. To provide epidemiological context for this expenditure–mortality relationship, Figure 6 presents annual reported/estimated female breast cancer cases, female breast cancer deaths, and breast cancer‐related SUS expenditures in Brazil from 2008 to 2021. Female breast cancer reported/estimated cases, death counts, and breast cancer‐related SUS expenditures in Brazil, 2008–2021. Annual female breast cancer reported/estimated cases, absolute female breast cancer deaths, and SUS‐recorded breast cancer‐related expenditures in Brazil from 2008 to 2021. The inclusion of reported/estimated cases provides epidemiological context for interpreting expenditure growth and mortality burden. Expenditures represent breast cancer‐related administrative spending captured in DATASUS and do not represent total societal or full‐pathway costs. Death counts are not age‐standardized mortality rates and should not be used alone to infer temporal changes in mortality risk. Toward a Value‐Based Oncology Framework At the ecological health‐system level, our findings emphasize the need for a strategic pivot from volume‐based to value‐based oncology in Brazil. Strengthening primary care integration with oncology networks to facilitate early diagnosis.Accelerating biosimilar adoption through procurement reform and incentivized local production.Regionalizing policy implementation to address disparities in cancer care capacity.Linking public investment to measurable outcome indicators, including survival, quality of life, and access metrics. Strengthening primary care integration with oncology networks to facilitate early diagnosis. Strengthening primary care integration with oncology networks to facilitate early diagnosis. Accelerating biosimilar adoption through procurement reform and incentivized local production. Accelerating biosimilar adoption through procurement reform and incentivized local production. Regionalizing policy implementation to address disparities in cancer care capacity. Regionalizing policy implementation to address disparities in cancer care capacity. Linking public investment to measurable outcome indicators, including survival, quality of life, and access metrics. Linking public investment to measurable outcome indicators, including survival, quality of life, and access metrics. Brazil has substantially expanded its oncologic therapeutic arsenal and institutional capacity; however, sustainable improvement requires that technology incorporation be accompanied by timely diagnosis, implementation capacity, regional equity, and outcome‐oriented evaluation (Figure 7). Directed acyclic graph (conceptual causal framework) for the hypothesized relationship between SUS‐recorded oncology expenditure and population‐level mortality. The DAG is conceptual rather than estimative. It makes explicit that expenditure may affect mortality indirectly through technology incorporation, diagnostic timeliness, treatment access, service capacity, and continuity of care, while population aging, cancer incidence, socioeconomic conditions, secular innovation, coding/reporting practices, and regional infrastructure may confound, mediate, or modify observed aggregate associations. Because these variables were not jointly measured at the national annual level, the present ecological analysis does not claim covariate‐adjusted causal identification. Methodological Limitations The principal limitation is the ecological population‐level time‐series design. Expenditure, mortality, demographic structure, and policy context are observed at aggregate levels and are not linked to individual patients; therefore, cross‐level inference is unsupported and ecological fallacy remains a central risk. Administrative reimbursement databases were not designed for clinically granular oncology research and may be affected by coding variability, underreporting, delayed registration, changes in reimbursement rules, and fragmentation across inpatient, outpatient, and mortality systems. They do not provide nationally harmonized longitudinal information on stage, molecular subtype, therapeutic intent, treatment sequence, adherence, recurrence, progression, or patient‐level survival. The expenditure series also captures SUS‐recorded administrative spending rather than the full societal or full‐pathway cost of cancer control, with incomplete representation of some screening, primary‐care diagnostic, referral, and indirect costs. A second limitation concerns outcome sensitivity and presentation. Age‐standardized mortality is the primary epidemiological metric because it reduces distortion from demographic aging, whereas absolute death counts are retained only as indicators of burden. Mortality remains a delayed and relatively insensitive medium‐term endpoint for prostate cancer and may not capture earlier gains in stage migration, diagnostic timeliness, progression control, or quality of life. The annual national series is also short for time‐series inference. For this reason, the revised manuscript avoids unsupported descriptors such as “weak correlation,” does not report unvalidated GLS or bivariate correlation estimates, and limits interpretation to descriptive temporal divergence. A third limitation concerns policy attribution. The four major milestones were closely spaced within a short annual series, and the data do not provide clean, independent pre‐ and post‐intervention segments for each event. Formal interrupted time‐series estimation would therefore be vulnerable to unstable coefficients, overlapping intervention effects, autocorrelation, and unmeasured time‐varying confounding [9]. The policy component is accordingly restricted to descriptive contextualization. Similarly, regional disparity is discussed using published evidence rather than study‐derived Gini or Theil coefficients because reproducible region‐year inequality inputs and estimates were not reported in the underlying manuscript dataset. Future evaluations should integrate annual standardized mortality with stage at diagnosis, diagnostic intervals, treatment‐initiation time, therapeutic intent, treatment sequence, regional service capacity, and survival. Region‐ or state‐level panels with transparent denominators would also permit reproducible inequality metrics and appropriately powered longitudinal models. Such designs would provide a stronger basis for evaluating whether incremental oncology spending improves access, process quality, and clinically meaningful outcomes. Conclusion This ecological population‐level time‐series analysis identifies a descriptive system‐level divergence in Brazil's oncology landscape: SUS‐recorded expenditure for breast and prostate cancer care increased substantially over the study period, while national age‐standardized mortality indicators showed comparatively limited proportional improvement within the same observational window. This conclusion is based on standardized mortality rather than absolute death counts; count‐based figures are retained only as burden indicators and are influenced by incidence, population growth, aging, and ascertainment. The study does not estimate a causal effect of expenditure, technology incorporation, or individual policies on patient outcomes. The findings should be interpreted as a health‐system signal rather than a judgment on the clinical effectiveness of specific therapies. Aggregate expenditure is an incomplete proxy for effective cancer‐system performance, particularly in a country with substantial territorial and socioeconomic heterogeneity. Published evidence indicates that diagnostic infrastructure, specialist availability, referral efficiency, radiotherapy capacity, pathology access, and continuity of care vary substantially across Brazil and may modify the translation of resources into outcomes. Thus, national expenditure growth and equitable clinical access are conceptually distinct, and an apparent temporal divergence at national level may coexist with meaningful benefit in specific patients, services, technologies, or regions. From a policy perspective, the results support a value‐oriented oncology framework that couples technology incorporation with early diagnosis, timely treatment initiation, equitable territorial distribution of services, transparent reimbursement pathways, and routine measurement of outcomes and access. Future studies should use reproducible annual age‐standardized rate tables, region‐level longitudinal panels, stage and time‐to‐treatment indicators, and survival outcomes to quantify these relationships with appropriate uncertainty and to distinguish expenditure growth from implementation effectiveness. Author Contributions Leonardo Paredes Pires: investigation, writing – original draft, writing – review and editing, visualization, methodology, formal analysis, data curation. Larissa Saldanha Fonseca: conceptualization, investigation, writing – original draft, methodology, writing – review and editing, software, formal analysis. Luciana Magalhães Rebelo Alencar: validation, visualization, software, project administration, supervision, data curation, writing – review and editing, writing – original draft. Ralph Santos‐Oliveira: conceptualization, funding acquisition, writing – original draft, writing – review and editing, visualization, methodology, formal analysis, supervision, data curation, resources. Eduardo Ricci‐Junior: writing – original draft, writing – review and editing, visualization, software, data curation, supervision. Funding This study was funded by the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro—FAPERJ—and by the Brazilian National Council for Scientific and Technological Development—CNPq. FAPERJ support included Cientista do Nosso Estado: E‐26/200.815/2021; Rede NanoSaude: E‐26/010.000981/2019; Temáticos: E‐26/211.269/2021; and Infraestrutura e Pesquisa na UEZO e UERJ: E‐26/211.207/2021. CNPq support included Bolsa de Produtividade 1B: 301069/2018‐2; Internacional: 440852/2023‐4; Universal: 401692/2023‐0; Medicina de Precisão: 444089/2023‐3 to Ralph Santos‐Oliveira; and Bolsa de Produtividade 2: 304774/2021‐9 to Luciana Alencar. Ethics Statement This study used anonymized, publicly available secondary aggregate data and did not involve direct contact with human participants, individual‐level patient data, or any intervention. Therefore, institutional ethical approval and informed consent were not required, in accordance with Brazilian Resolution CNS 510/2016. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.